Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.33 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25406552 | 0.98 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3SLC6A1GABRA5 | |
| SCHEMBL222368 | 0.86 | SLC6A1 (0.49) | SLC6A2SLC6A4SLC6A3SLC6A1GABRA5 | |
| SCHEMBL3613801 | 0.86 | SLC6A1 (0.49) | SLC6A2SLC6A4SLC6A3SLC6A1GABRA5 | |
| SCHEMBL222367 | 0.86 | SLC6A1 (0.49) | SLC6A2SLC6A4SLC6A3SLC6A1GABRA5 | |
| SCHEMBL29244744 | 0.83 | CPN1 (0.43) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL1062304 | 0.83 | CPN1 (0.43) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL16292529 | 0.82 | ALOX5 (0.39) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL927784 | 0.81 | GABRA5 (0.39) | SLC6A2SLC6A4SLC6A1GABRA5GABRB2 | |
| SCHEMBL345833 | 0.81 | SLC6A1 (0.32) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Oxalic Acid SCHEMBL1623722 | 0.81 | CPN1 (0.41) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3995495-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3649108-A1 | 2-(4-CHLOROPHENOXY)-N-((1 -(2-(4-CHLOROPHENOXY)ETHYNAZETIDIN-3-YL)METHYL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-05-13 | — | — | EP | disclosed |
| US-20200140383-A1 | 2-(4-CHLOROPHENOXY)-N-((1 -(2-(4-CHLOROPHENOXY)ETHYNAZETIDIN-3-YL)METHYL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-05-07 | — | — | US | disclosed |
| EP-3626717-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2020-03-25 | — | — | EP | disclosed |
| WO-2019008507-A1 | 2-(4-CHLOROPHENOXY)-N-((1 -(2-(4-CHLOROPHENOXY)ETHYNAZETIDIN-3-YL)METHYL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-10 | — | — | WO | disclosed |
| US-20180354939-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-12-13 | — | — | US | disclosed |
| US-10087174-B2 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180030045-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-02-01 | — | — | US | disclosed |
| EP-2915813-B1 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2015-09-24 | — | — | US | disclosed |
| EP-2915813-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-09-09 | — | — | EP | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| EP-2905283-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-08-12 | — | — | EP | disclosed |
| WO-2015057659-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
| US-20150105370-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-8217029-B2 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-10 | — | — | US | disclosed |
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | HDAC2, HDAC1, HDAC11 | SLC6A2 1855/4885SLC6A4 2139/4885SLC6A3 1308/4885 |
| US-10087174-B2 | Selectively substituted quinoline compounds | SSB, TLR7, TLR8 | SLC6A2 752/4885SLC6A4 1161/4885SLC6A3 1340/4885 |
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | SLC6A2 2920/4885SLC6A4 3760/4885SLC6A3 3918/4885 |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | SLC6A2 2930/4885SLC6A4 2441/4885SLC6A3 3589/4885 |
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | OXA1L, XDH, UBE2D3 | SLC6A2 4581/4885SLC6A4 4649/4885SLC6A3 3724/4885 |
| US-20180030045-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | SLC6A2 752/4885SLC6A4 1161/4885SLC6A3 1340/4885 |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | HDAC2, HDAC1, HDAC11 | SLC6A2 1855/4885SLC6A4 2139/4885SLC6A3 1308/4885 |
| US-20180354939-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | SLC6A2 879/4885SLC6A4 1309/4885SLC6A3 1636/4885 |
| US-20200140383-A1 | 2-(4-CHLOROPHENOXY)-N-((1 -(2-(4-CHLOROPHENOXY)ETHYNAZETIDIN-3-YL)METHYL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES | ATF4, EIF2B4, EIF2B5 | SLC6A2 2167/4885SLC6A4 1296/4885SLC6A3 1893/4885 |
| US-20150105370-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | SLC6A2 752/4885SLC6A4 1161/4885SLC6A3 1340/4885 |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | SLC6A2 2930/4885SLC6A4 2441/4885SLC6A3 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.